HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 01-02-2014, 11:46 PM   #1
donocco
Senior Member
 
Join Date: Oct 2013
Posts: 474
Tivatinib (ARQ-197)

I dont know if this investigational drug has been mentioned before. It is an inhibitor of C-MET which is the Hepatocyte Growth Factor Tyrosine Kinase. Apparently C-Met is overactive in various cancers. Tivatinib has been tried in Non Small Cell Cancer of the lung and Hepatocellular Carcinoma with some positive results.

The usual dosage seems to be 360mg twice daily and the side effects are anemia, Neutropenia, Fatigue and appetite loss.

Paul
donocco is offline   Reply With Quote
 

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:33 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter